Every 8-K that KalVista Pharmaceuticals, Inc. (KALV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KALV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KALV filings page.
KalVista Pharmaceuticals has been acquired by Chiesi Group and is being taken private. Chiesi completed a tender offer for all KalVista common shares at $27.00 in cash per share, with approximately 43,152,532 shares, or 77.8% of outstanding shares, validly tendered.
After the tender offer, a short-form merger under Delaware law was completed, converting all remaining shares into the right to receive the same cash price and making KalVista a wholly owned Chiesi subsidiary. KalVista’s stock has ceased trading on the Nasdaq Global Market, and the company plans to deregister its shares and suspend SEC reporting.
The filing also details updated terms for KalVista’s 3.250% Convertible Senior Notes due 2031, which are now convertible into $1,606.28 in cash per $1,000 principal amount, executive transaction bonuses, a tax gross-up agreement for the CFO, termination of equity plans, and a full board change with Chiesi’s designee becoming sole director.
KalVista Pharmaceuticals agreed to be acquired by Chiesi Group in an all-cash transaction. Chiesi will launch a tender offer to buy all outstanding KalVista shares for $27.00 per share, implying a total deal value of about $1.9 billion.
The offer is conditioned on a majority of shares being tendered, antitrust and foreign investment clearances, and customary accuracy, covenant and no–material-adverse-effect conditions. After the tender offer, a back-end merger under Section 251(h) of Delaware law will make KalVista a wholly owned Chiesi subsidiary.
KalVista’s board unanimously approved the merger agreement and recommends stockholders tender their shares. The agreement includes typical non-solicitation and fiduciary out provisions and a $66.4 million termination fee payable to Chiesi in specified circumstances. The parties expect closing in Q3 2026, subject to conditions.
KalVista Pharmaceuticals reported results for the eight-month transition period ended December 31, 2025, reflecting its shift to a calendar fiscal year. The company generated $49.1 million in global net product revenue from EKTERLY, the first and only oral on-demand treatment for hereditary angioedema.
Adoption is highlighted by 1,702 US patient start forms from launch through February and launches in markets including Germany and Japan through partner Kaken. Despite this growth, KalVista reported a net loss of $109.5 million and basic and diluted net loss per share of $2.03 for the period.
On the balance sheet, cash, cash equivalents and marketable securities were $300.2 million as of December 31, 2025, with total assets of $335.4 million and total liabilities of $338.1 million, resulting in a modest stockholders’ deficit. Management reiterated plans to expand EKTERLY access and advance pediatric filings.
KalVista Pharmaceuticals reported preliminary global net revenue of approximately $35 million for the quarter and $49 million for the eight‑month transition period ended December 31, 2025. These figures are early estimates and rely on the company’s financial closing procedures and the completion of an audit of its financial statements for that transition period. The company emphasized that the final audited results could differ materially from these preliminary numbers. KalVista also released a press release and an updated corporate presentation, which are attached as exhibits to this report.
KalVista Pharmaceuticals (KALV) furnished an update on its latest results. The company reported financial results for the quarter ended September 30, 2025 and provided a related press release as Exhibit 99.1 to this Form 8-K.
The information under Item 2.02, including Exhibit 99.1, is expressly stated as “furnished” and not “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically noted in a future filing.
KalVista Pharmaceuticals (KALV) disclosed an employment agreement for a newly named executive, Mr. Arif, detailing compensation and termination protections. The agreement sets a $520,000 base salary and an annual bonus target equal to 40% of base salary. Mr. Arif will receive stock options to purchase 100,000 shares that vest over four years with 1/4 vesting after one year and thereafter 1/48th monthly vesting, subject to continued service.
If terminated by the company without cause or by Mr. Arif for good reason, he is entitled to a lump-sum payment equal to 12 months of base salary and 12 months of COBRA reimbursement. Within two years after a defined change in control, similar termination triggers (company without cause or employee for good reason) add a lump-sum payment equal to 12 months of base salary, a lump-sum equal to his full target bonus for the fiscal year, 12 months of COBRA reimbursement, and full vesting of outstanding unvested equity awards (with performance awards deemed at target or actual if determinable).
The filing includes a Form of Indemnification Agreement reference and notes a press release dated October 6, 2025, signed by CFO Brian Piekos.
KalVista Pharmaceuticals, Inc. disclosed the appointment of Ms. Sensenig as a non-employee director and the associated compensation arrangements. Her initial board award consists of options to purchase 45,000 shares of the company's common stock. She will receive an annual cash retainer of $42,500 plus an additional $10,000 per year for service on the Audit Committee. The disclosure is a routine corporate governance item describing director pay terms.
KalVista Pharmaceuticals, Inc. filed an 8-K reporting the execution of an indenture for a new convertible debt instrument and related press releases. The filing references an indenture dated September 29, 2025 between the company and U.S. Bank Trust Company, N.A., which includes the form of 3.250% Convertible Senior Notes due 2031. The company also filed two press releases dated September 24, 2025 announcing the proposed offering and the pricing of the Notes, and submitted the Cover Page Interactive Data File. The filing is signed by Brian Piekos, Chief Financial Officer.
KalVista Pharmaceuticals, Inc. filed a current report to share its financial results for the fiscal quarter ended July 31, 2025. The results are contained in a press release furnished as Exhibit 99.1.
The company specifies that this earnings information is furnished under Item 2.02 of the Exchange Act, not deemed filed, and it is signed on behalf of the company by Chief Executive Officer Benjamin L. Palleiko.
KalVista Pharmaceuticals, Inc. has set June 18, 2026 as the date of its 2026 Annual Meeting of Stockholders. The specific time and location will be provided in the company’s definitive proxy statement to be filed before the meeting.
Because this meeting date differs by more than 30 days from the prior year’s annual meeting, stockholder proposals seeking inclusion in the 2026 proxy materials must be submitted in writing to the Corporate Secretary by January 6, 2026. Under the company’s Amended and Restated Bylaws, stockholders wishing to present other proposals at the meeting or nominate directors must deliver notice by August 31, 2025, and must also comply with the universal proxy requirements of Rule 14a-19 for any competing director nominations.